BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod
Bristol Myers Squibb said the FDA granted its first approval for the CELMoD therapy Zenbexus (iberdomide) for previously treated multiple myeloma in combination with Johnson & Johnson’s Darzalex and dexamethasone. Approval is accelerated using MRD as a surrogate endpoint. In Excaliber-RRMM, MRD-negative response was 41% vs 21% with a Darzalex plus Velcade regimen; PFS remains a confirmatory endpoint.
How this was made
The 30-second read
Why it matters
This is a regulatory milestone that both validates the CELMoD modality and sets an FDA benchmark for MRD-driven accelerated approvals, while also creating execution risk tied to confirmatory PFS evidence and narrower initial patient fit.
Market read
Traders can reassess BMY’s oncology growth outlook as a new, FDA-cleared modality emerges, but should weigh confirmatory PFS timing and label constraints.
What to watch
The article notes boxed warnings (embryo-fetal toxicity, thromboembolism) and ongoing Excaliber-Maintenance and mezigdomide review timelines, which can drive volatility around safety, uptake, and future data.
Background
Zenbexus (iberdomide) is approved as a CELMoD therapy in combination with Darzalex and dexamethasone for previously treated multiple myeloma, with MRD used as the accelerated-approval surrogate.
Ticker impact
Bristol Myers Squibb secured the first FDA approval for its CELMoD therapy Zenbexus (iberdomide) in combination for previously treated multiple myeloma.
Near-term upside bias as traders price in a new, validated modality and potential sales ramp, tempered by confirmatory PFS risk and limited CD38-pretreated data.
The article reports a first-in-class FDA milestone, includes trial efficacy numbers (MRD-negative response), and flags confirmatory evidence requirements and label limitations.
Market effects
Validates MRD as a surrogate endpoint for accelerated approval in myeloma, potentially shifting trial design expectations across oncology developers.
US biotech sentiment may improve for targeted protein degradation and myeloma franchises tied to MRD endpoint strategies.
Regulatory precedent may influence global development programs and endpoint selection beyond the US.
Counterpoint
Accelerated approval based on MRD can be de-risked only after confirmatory PFS readout; label limitations for CD38-pretreated patients may cap near-term uptake.
Key entities
- companyBristol Myers Squibb
Secured the first FDA approval for a CELMoD therapy, Zenbexus, in combination for previously treated multiple myeloma.
- drugZenbexus (iberdomide)
CELMoD therapy cleared by FDA with accelerated approval using MRD as the surrogate endpoint.
- drugDarzalex (daratumumab)
Partner therapy in the approved Zenbexus combination regimen.
